3,3'-Dimethoxybenzidine dihydrochloride: Target Organs and Levels of Evidence for TR-372
Toxicology and Carcinogenesis Studies of 3,3'-Dimethoxybenzidine Dihydrochloride (CASRN 20325-40-0) in F344/N Rats (Drinking Water Studies)
Chemical (Study Title) CASRN | Peer Review Date | Route/Exposure Levels | Study Laboratory |
---|
3,3'-Dimethoxybenzidine dihydrochloride 20325-40-0 | 06/27/1989 | Dosed-Water R: 0,80,170,330 PPM /70,45,75,70 PER GROUP RESPECTIVELY | Hazleton, Vienna |
Levels of Evidence
Male Rats: Clear Evidence
Type | Organ/Tissue (Lesion) |
---|
Neoplastic Lesions | - Skin:
BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60
- Liver:
NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60
- Large Intestines:
ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60
- Oral Cavity:
SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60
- Zymbal Gland:
ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60
- Preputial Gland:
ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59
- Mesothelium (Abdominal Cavity/Tunica Vaginalis):
MESOTHELIOMA 2/60 1/45 7/75 6/60
|
May Have Been Related | - Brain:
ASTROCYTOMA 0/60 2/44 3/75 1/60
|
Non-Neoplastic Lesions | - SPLEEN: HEMATOPOIETIC CELL PROLIFERATION 3/60 13/42 43/74 38/59
- LUNG: INFILTRATION, CELLULAR, HISTIOCYTIC 0/60 3/44 10/75 6/60
- HEART: ATRIUM, THROMBUS 3/60 15/44 27/75 23/60
- LIVER: DEGENERATION, CYSTIC 13/60 23/45 34/74 28/60; DEGENERATION, CENTRILOBULAR, DIFFUSE 0/60 4/45 9/74 10/60; NECROSIS, CENTRILOBULAR 4/60 13/45 10/74 6/60
|
Female Rats: Clear Evidence
Type | Organ/Tissue (Lesion) |
---|
Neoplastic Lesions | - Zymbal Gland:
ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60
- Clitoral Gland:
ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55
- Mammary Gland:
ADENOCARCINOMA 1/60 2/45 14/75 20/60
- Skin:
SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60
- Oral Cavity:
SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60
- Large Intestines:
ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60
- Liver:
NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60
- Uterus/Cervix:
ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59
|
Non-Neoplastic Lesions | - LUNG: INFILTRATION, CELLULAR, HISTIOCYTIC 0/60 3/45 4/75 18/60
- LIVER: DEGENERATION, CYSTIC 1/60 2/44 1/75 5/60; DEGENERATION, CENTRILOBULAR 1/60 3/44 8/75 5/60; NECROSIS CENTRILOBULAR 1/60 2/44 6/75 5/60
- SPLEEN: HEMATOPOIETIC CELL PROLIFERATION 3/60 22/44 50/75 47/60
|